Texas
|
|
59-2219994
|
(State or other jurisdiction of incorporation or
organization)
|
|
(I.R.S. Employer Identification No.)
|
1200
Summit Ave, Suite 414, Fort Worth, Texas 76102
|
(Address
of principal executive offices)
(817)
529-2300
(Registrant’s telephone number, including area
code)
|
Large
accelerated filer
☐
|
|
Accelerated
filer
☐
|
|
Non-accelerated
filer
☑
|
|
Smaller
reporting company
☑
|
Emerging
growth company
☐
|
|
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
2019
|
2020
|
$150,887
|
2021
|
151,317
|
2022
|
151,333
|
2023
|
154,271
|
2024
|
77,870
|
Total lease
payments
|
685,678
|
Less imputed
interest
|
(86,761)
|
Present value of
lease liabilities
|
$598,917
|
Report of Independent Registered Public Accounting
Firm
|
18
|
|
|
Consolidated Balance Sheets
|
19
|
|
|
Consolidated Statements of Operations
|
20
|
|
|
Consolidated Statements of Changes in Stockholders’ Equity
(Deficit)
|
21
|
|
|
Consolidated Statements of Cash Flows
|
22
|
|
|
Notes to the Consolidated Financial Statements
|
23
|
|
Successor
|
Successor
|
|
December 31,
|
December 31,
|
Assets
|
2019
|
2018
|
Current assets
|
|
|
Cash
and cash equivalents
|
$6,611,928
|
$176,421
|
Accounts
receivable, net of allowance for bad debt of $60,012 and
$0
|
1,285,165
|
1,022,500
|
Royalty
receivable
|
50,250
|
-
|
Inventory,
net of allowance for obsolescence of $43,650 and $484
|
746,519
|
465,314
|
Prepaid
and other assets
|
161,902
|
26,446
|
Total current assets
|
8,855,764
|
1,690,681
|
|
|
|
Long-term assets
|
|
|
Property,
plant and equipment, net of accumulated depreciation of $60,694 and
$511
|
204,953
|
18,777
|
Right
of use assets – operating leases
|
585,251
|
-
|
Intangible
assets, net of accumulated amortization of $603,580 and
$0
|
1,471,194
|
-
|
Total long-term assets
|
2,261,398
|
18,777
|
|
|
|
Total assets
|
$11,117,162
|
$1,709,458
|
|
|
|
Liabilities and shareholders' equity
|
|
|
Current liabilities
|
|
|
Accounts
payable
|
$337,504
|
$156,727
|
Accounts
payable – related party
|
68,668
|
36,203
|
Accrued
royalties and expenses
|
528,060
|
228,606
|
Accrued
bonus and commissions
|
1,588,056
|
701,125
|
Operating
lease liability - current
|
117,533
|
-
|
Line
of credit
|
-
|
-
|
Total current liabilities
|
2,639,821
|
1,122,661
|
|
|
|
Long-term liabilities
|
|
|
Operating
lease liability – long term
|
481,384
|
-
|
Convertible
notes payable – related party
|
1,500,000
|
-
|
Accrued
interest - related party
|
103,557
|
-
|
Total long-term liabilities
|
2,084,941
|
-
|
|
|
|
Total liabilities
|
4,724,762
|
1,122,661
|
|
|
|
Shareholders' equity
|
|
|
Series
F Convertible Preferred Stock: $10 par value, 1,200,000 shares
authorized; 1,136,815 issued and outstanding as of December 31,
2019 and 1,136,815 issued and outstanding as of December 31,
2018
|
11,368,150
|
11,368,150
|
Common
Stock: $0.001 par value, 20,000,000 shares authorized; 3,571,001
issued and outstanding as of December 31, 2019 and none issued and
outstanding as of December 31, 2018
|
3,571
|
-
|
Additional
paid-in capital
|
(2,081,829)
|
(10,919,639)
|
Retained
earnings (accumulated deficit)
|
(2,675,802)
|
138,286
|
Total Sanara MedTech shareholders' equity
|
6,614,090
|
586,797
|
Equity attributable
to noncontrolling interest
|
(221,690)
|
-
|
Total shareholders' equity
|
6,392,400
|
586,797
|
|
|
|
Total liabilities and shareholders' equity
|
$11,117,162
|
$1,709,458
|
|
Successor
|
Predecessor
|
|
|
January 1, 2019 – December 31, 2019
|
August 28, 2018-December 31, 2018
|
January 1, 2018-August 27, 2018
|
|
|
|
|
Revenues
|
$11,766,763
|
$3,006,320
|
$5,773,552
|
|
|
|
|
Cost of goods sold
|
1,209,300
|
371,421
|
480,703
|
|
|
|
|
Gross profit
|
10,557,463
|
2,634,899
|
5,292,849
|
|
|
|
|
Operating expenses
|
|
|
|
Selling,
general and administrative expenses
|
13,067,569
|
2,519,469
|
5,126,650
|
Depreciation
and amortization
|
119,951
|
511
|
56,425
|
Bad
debt expense
|
110,000
|
-
|
12,558
|
Total operating expenses
|
13,297,520
|
2,519,980
|
5,195,633
|
|
|
|
|
Operating income (loss)
|
(2,740,057)
|
114,919
|
97,216
|
|
|
|
|
Other income / (expense)
|
|
|
|
Other
income
|
10,198
|
23,367
|
570
|
Interest
expense
|
(105,919)
|
-
|
(60,608)
|
Total other income / (expense)
|
(95,721)
|
23,367
|
(60,038)
|
|
|
|
|
Net income (loss)
|
(2,835,778)
|
138,286
|
37,178
|
|
|
|
|
Less:
Net loss attributable to noncontrolling interest
|
(21,690)
|
-
|
-
|
|
|
|
|
Net income (loss) attributable to Sanara MedTech Inc.
|
(2,814,088)
|
138,286
|
37,178
|
|
|
|
|
Series
C Preferred Stock dividends
|
-
|
-
|
(28,061)
|
Series
C Preferred Stock inducement dividends
|
-
|
-
|
(103,197)
|
|
|
|
|
Net income (loss) attributable to Sanara MedTech common
shareholders
|
$(2,814,088)
|
$138,286
|
$(94,080)
|
|
|
|
|
Basic
loss per share of Common stock
|
$(1.32)
|
$-
|
$(0.05)
|
|
|
|
|
Diluted
loss per share of Common Stock
|
$(1.32)
|
$-
|
$(0.05)
|
|
|
|
|
Weighted
average number of common shares outstanding basic
|
2,132,745
|
-
|
2,068,941
|
|
|
|
|
Weighted
average number of common shares outstanding diluted
|
2,132,745
|
-
|
2,068,941
|
Predecessor
|
Preferred Stock
Series C
|
Common
Stock
|
Additional
|
|
|
|
Total
|
|||
|
$10 par
value
|
$0.001 par
value
|
Paid-In
|
Treasury
Stock
|
Accumulated
|
Noncontrolling
|
Shareholders'
|
|||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Shares
|
Amount
|
Income/(Deficit)
|
Interest
|
Equity
(Deficit)
|
Balance at December 31,
2017
|
85,561
|
$855,610
|
1,134,279
|
$1,134
|
$46,114,357
|
(41)
|
$(120)
|
$(46,868,443)
|
$-
|
$102,538
|
Conversion of Series C Preferred
Shares
|
(85,561)
|
(855,610)
|
855,605
|
855
|
854,755
|
-
|
-
|
-
|
-
|
-
|
Series C
Dividend
|
-
|
-
|
150,067
|
150
|
(150)
|
-
|
-
|
-
|
-
|
-
|
Common Stock issued for conversion
of debt
|
-
|
-
|
226,514
|
227
|
1,585,367
|
-
|
-
|
-
|
-
|
1,585,594
|
Recognition of stock option
expense
|
-
|
-
|
-
|
-
|
14,867
|
-
|
-
|
-
|
-
|
14,867
|
Net income
(loss)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
37,178
|
-
|
37,178
|
Balance at August 27,
2018
|
-
|
$-
|
2,366,465
|
$2,366
|
$48,569,196
|
(41)
|
$(120)
|
$(46,831,265)
|
$-
|
$1,740,177
|
Successor
|
Preferred Stock
Series F
|
Common
Stock
|
Additional
|
|
|
|
Total
|
|||
|
$10 par
value
|
$0.001 par
value
|
Paid-In
|
Treasury
Stock
|
Accumulated
|
Noncontrolling
|
Shareholders'
|
|||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Shares
|
Amount
|
Income/(Deficit)
|
Interest
|
Equity
(Deficit)
|
Issuance of preferred stock upon
formation on August 28, 2018
|
1,136,815
|
$11,368,150
|
-
|
$-
|
$(10,919,639)
|
-
|
$-
|
$-
|
$-
|
$448,511
|
Net income
(loss)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
138,286
|
-
|
138,286
|
Balance at December 31,
2018
|
1,136,815
|
$11,368,150
|
-
|
$-
|
$(10,919,639)
|
-
|
$-
|
$138,286
|
$-
|
$586,797
|
Reverse
recapitalization
|
-
|
-
|
2,366,465
|
2,366
|
(1,159,929)
|
(41)
|
-
|
-
|
-
|
(1,157,563)
|
Treasury stock
retirement
|
-
|
-
|
(41)
|
-
|
-
|
41
|
-
|
-
|
-
|
-
|
Repurchase and cancellation of
fractional shares
|
-
|
-
|
(243)
|
-
|
(1,061)
|
-
|
-
|
-
|
-
|
(1,061)
|
Private placement stock
issue
|
-
|
-
|
1,204,820
|
1,205
|
9,998,800
|
-
|
-
|
-
|
-
|
10,000,005
|
Advance on future noncontrolling
interest distribution
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(200,000)
|
(200,000)
|
Net income
(loss)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(2,814,088)
|
(21,690)
|
(2,835,778)
|
Balance at December 31,
2019
|
1,136,815
|
$11,368,150
|
3,571,001
|
$3,571
|
$(2,081,829)
|
-
|
$-
|
$(2,675,802)
|
$(221,690)
|
$6,392,400
|
|
Successor
|
Predecessor
|
|
|
January 1, 2019 – December 31, 2019
|
August 28, 2018-December 31, 2018
|
January 1, 2018-August 27, 2018
|
|
|
|
|
Cash flows from operating activities:
|
|
|
|
Net
income (loss)
|
$(2,835,778)
|
$138,286
|
$37,178
|
Adjustments
to reconcile net income to net cash used in operating
activities
|
|
|
|
Depreciation
and amortization
|
119,951
|
511
|
56,425
|
Interest expense on
convertible debt
|
61,934
|
-
|
60,608
|
Loss on disposal of
asset
|
15,944
|
-
|
-
|
Bad debt
expense
|
110,000
|
-
|
12,558
|
Recognition of
vesting stock option expense
|
-
|
-
|
14,867
|
Changes
in assets and liabilities:
|
|
|
|
(Increase)
decrease in accounts receivable
|
(324,368)
|
(1,022,500)
|
(313,969)
|
(Increase)
decrease in inventory
|
(281,205)
|
(16,803)
|
262,886
|
(Increase)
decrease in prepaid and other assets
|
(455,960)
|
(26,446)
|
(23,320)
|
Increase
(decrease) in accounts payable
|
(65,037)
|
156,727
|
189,388
|
Increase
(decrease) in accounts payable related parties
|
(19,599)
|
36,203
|
(36,097)
|
Increase
(decrease) in accrued royalties and expenses
|
282,004
|
228,606
|
(170,467)
|
Increase
(decrease) in accrued liabilities
|
1,224,713
|
701,125
|
231,313
|
Net cash flows provided by (used in) operating
activities
|
(2,167,401)
|
195,709
|
321,370
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
Purchase
of property and equipment
|
(182,825)
|
(19,288)
|
(8,482)
|
Cash
received in reverse acquisition
|
508,973
|
-
|
-
|
Repurchase
and cancellation of fractional shares
|
(1,061)
|
-
|
-
|
Proceeds
from disposal of assets
|
301
|
|
|
Purchase
of intangible assets
|
(1,522,485)
|
-
|
-
|
Net cash flows used in investing activities
|
(1,197,097)
|
(19,288)
|
(8,482)
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
Draw
on line of credit
|
2,200,000
|
-
|
-
|
Payment
on line of credit
|
(2,200,000)
|
|
|
Private
placement stock issue
|
10,000,005
|
-
|
-
|
Advance
on future noncontrolling interest distribution
|
(200,000)
|
-
|
-
|
Net cash flows from financing activities
|
9,800,005
|
-
|
-
|
|
|
|
|
Net increase in cash
|
6,435,507
|
176,421
|
312,888
|
Cash and cash equivalents, beginning of period
|
176,421
|
-
|
463,189
|
Cash and cash equivalents, end of period
|
$6,611,928
|
$176,421
|
$776,077
|
|
|
|
|
Cash paid during the period for:
|
|
|
|
Interest
|
$43,985
|
$-
|
$-
|
Income
taxes
|
-
|
-
|
-
|
|
|
|
|
Supplemental non-cash investing and financing
activities:
|
|
|
|
Common
stock issued for dividends on Series C Preferred Stock
|
-
|
-
|
15,007
|
Common
stock issued for conversion of Series C Preferred
Stock
|
-
|
-
|
85,561
|
Common
stock issued for conversion of Related Party debt and
interest
|
-
|
-
|
1,585,594
|
Preferred
Shares issued for inventory contribution
|
-
|
448,511
|
-
|
Common
stock issued in reverse capitalization; less cash received of
$508,973
|
1,666,537
|
-
|
-
|
|
Successor
|
Predecessor
|
|
|
January 1, 2019 – December 31, 2019
|
August 28, 2018-December 31, 2018
|
January 1, 2018-August 27, 2018
|
Numerator
for basic and diluted net income (loss) per share:
|
|
|
|
Net
income (loss) attributable to Sanara MedTech
|
$(2,814,088)
|
$138,286
|
$37,178
|
Series
C Preferred Stock dividends
|
-
|
-
|
(28,061)
|
Series
C Preferred Stock inducement dividends
|
-
|
-
|
(103,197)
|
Basic
net income (loss) attributable to Sanara MedTech common
shareholders
|
$(2,814,088)
|
$138,286
|
$(94,080)
|
Denominator
for basic and diluted net income (loss) per share:
|
|
|
|
Weighted
average shares used to compute diluted net income (loss) per
share
|
2,132,745
|
-
|
2,068,941
|
|
|
|
|
Basic
and diluted net income (loss) per share attributable to common
shareholders
|
$(1.32)
|
$-
|
$(0.05)
|
|
Successor
|
Predecessor
|
|
|
January 1, 2019 – December 31, 2019
|
August 28, 2018-December 31, 2018
|
January 1, 2018-August 27, 2018
|
|
|
|
|
Options
|
2,059
|
-
|
-
|
Convertible
debt
|
178,173
|
-
|
-
|
Preferred
Shares
|
2,273,630
|
2,273,630
|
-
|
1. Identification of the contract with a
customer
|
2. Identification of the performance obligations in
the contract
|
3. Determination of the transaction
price
|
4. Allocation of the transaction price to the
performance obligations in the contract
|
5. Recognition of revenue when, or as, the Company
satisfies a performance obligation
|
|
Successor
|
Successor
|
|
December 31,
|
December 31,
|
|
2019
|
2018
|
|
|
|
Computers
|
$87,310
|
$5,147
|
Office
Equipment
|
22,312
|
-
|
Furniture
and fixtures
|
153,995
|
3,328
|
Leasehold
Improvements
|
2,030
|
-
|
Capital
in progress
|
-
|
10,813
|
|
265,647
|
19,288
|
|
|
|
Less
accumulated depreciation
|
(60,694)
|
(511)
|
|
|
|
Property
and equipment, net
|
$204,953
|
$18,777
|
1. Identification of the contract with a
customer
|
2. Identification of the performance obligations in
the contract
|
3. Determination of the transaction
price
|
4. Allocation of the transaction price to the
performance obligations in the contract
|
5. Recognition of revenue when, or as, the Company
satisfies a performance obligation
|
|
Successor
|
Predecessor
|
|
|
Twelve Months Ended
December 31,
2019
|
August 28, 2018-December 31, 2018
|
January 1, 2018-August 27, 2018
|
Product
sales revenue
|
$11,607,638
|
$3,006,320
|
$5,639,552
|
Royalty
revenue
|
159,125
|
-
|
134,000
|
Total Revenue
|
$11,766,763
|
$3,006,320
|
$5,773,552
|
|
|
Principal Amount
|
Accrued Interest
|
||
Note Payable
|
Terms of the agreement
|
2019 Successor
|
2018 Successor
|
2019 Successor
|
2018 Successor
|
|
|
|
|
|
|
August 27, 2018
Promissory Note
|
A $1,500,000 note
payable (i) interest accrues at 5% per annum and compounds
quarterly (ii) original maturity date of March 1, 2021
|
$1,500,000
|
$-
|
$103,557
|
$-
|
|
|
|
|
|
|
Total
|
|
$1,500,000
|
$-
|
$103,557
|
$-
|
|
|
|
|
|
Year Ending December 31,
|
Amount
|
|
|
2020
|
$122,998
|
2021
|
122,998
|
2022
|
120,583
|
2023
|
115,503
|
2024
|
115,503
|
Thereafter
|
873,609
|
Total
|
$1,471,194
|
|
2019 Successor
|
2018 Successor
|
Net
operating loss carry forwards, (21% as of December 31,
2019)
|
$1,876,114
|
$-
|
Valuation
allowance
|
(1,876,114)
|
-
|
Net
non-current deferred tax asset
|
$-
|
$-
|
|
2019 Successor
|
2018 Successor
|
|
|
|
Expected
federal income tax benefit
|
$605,767
|
$-
|
Goodwill
amortization
|
65,957
|
-
|
Change
in valuation allowance
|
(294,050)
|
-
|
NOL
carryover reduced by expiration
|
(302,134)
|
-
|
Pass
through entity income allocation
|
(94,151)
|
-
|
Reserve
for bad debt
|
(29,741)
|
-
|
Stock-based
compensation
|
48,352
|
-
|
Income
tax expense (benefit)
|
$-
|
$-
|
NAME
|
|
AGE
|
|
POSITION
|
|
YEAR FIRST ELECTED
|
Ronald
T. Nixon
|
|
64
|
|
Executive
Chairman
|
|
2019
|
James
W. Stuckert
|
|
82
|
|
Director
|
|
2015
|
S. Oden
“Denny” Howell Jr.
|
|
80
|
|
Director
|
|
2015
|
J.
Michael Carmena
|
|
64
|
|
Vice
Chairman
|
|
2019
|
Ann
Beal Salamone
|
|
69
|
|
Director
|
|
2019
|
Kenneth
E. Thorpe
|
|
63
|
|
Director
|
|
2019
|
NAME
|
|
AGE
|
|
POSITION
|
Zachary
B. Fleming
|
|
45
|
|
Co-Chief
Operating Officer and President, Surgical
|
Shawn
M. Bowman
|
|
44
|
|
Co-Chief
Operating Officer and President, Wound Care
|
Michael
D. McNeil
|
|
54
|
|
Chief
Financial Officer
|
J.
Michael Carmena
|
|
64
|
|
Principal
Executive Officer
|
Name and
Principal Position
|
|
Year
|
Salary
|
Bonus
|
Stock
Awards
|
Option Awards
(a)
|
Non-equity
incentive compensation
|
Non-qualified
deferred compensation earnings
|
All other
compen-sation
|
Total
|
|
|
|
($)
|
($)
|
($)
|
($)
|
($)
|
($)
|
($)
|
($)
|
|
|
|
|
|
|
|
|
|
|
|
Zachary B. Fleming, Co-Chief
Operating Officer and President, Surgical
|
|
2019
|
205,667
|
90,000
|
-
|
-
|
-
|
-
|
-
|
295,667
|
|
|
2018
|
161,452
|
68,000
|
-
|
-
|
-
|
-
|
-
|
229,452
|
|
|
|
|
|
|
|
|
|
|
|
Shawn M. Bowman, Co-Chief Operating
Officer and President, Wound Care
|
|
2019
|
205,667
|
80,000
|
-
|
-
|
-
|
-
|
-
|
285,667
|
|
|
2018
|
58,833
|
37,000
|
-
|
-
|
-
|
-
|
-
|
95,833
|
|
|
|
|
|
|
|
|
|
|
|
J. Michael Carmena, Principal
Executive Officer
|
|
2019
|
209,600
|
75,000
|
-
|
-
|
-
|
-
|
-
|
284,600
|
|
|
2018
|
207,107
|
60,000
|
-
|
-
|
-
|
-
|
-
|
267,107
|
|
|
|
|
|
|
|
|
|
|
|
Michael D. McNeil, Chief Financial
Officer
|
|
2019
|
169,500
|
63,000
|
-
|
-
|
-
|
-
|
-
|
232,500
|
|
|
2018
|
123,625
|
45,300
|
-
|
4,472
|
-
|
-
|
-
|
173,197
|
|
OPTION
AWARDS
|
|||
Name
|
Number of
Securities Underlying Unexercised Options
(Exercisable)
|
Number of
Securities Underlying Unexercised Options
(Unexercisable)
|
Option Exercise
Price ($)
|
Option
Expiration Date
|
J.
Michael Carmena
|
5,000
|
-
|
6.00
|
12/31/2022
|
Michael
D. McNeil
|
1,000
|
-
|
6.00
|
4/13/2023
|
Zachary
B. Fleming
|
2,000
|
-
|
6.00
|
12/31/2022
|
|
8,000
|
-
|
|
|
Plan
Category
|
Number of shares
to be issued upon the exercise of outstanding options
|
Weighted average
exercise price of outstanding options
|
Number of shares
remaining available for future issuance under equity compensation
plans (excluding shares reflected in the 2nd column)
|
Equity compensation
plans approved by shareholders
|
11,500
|
$6.00
|
1,988,500
|
Equity compensation
plans not approved by shareholders
|
—
|
—
|
—
|
|
Common Stock
|
|
OFFICERS AND DIRECTORS:
|
Number of Shares Beneficially Owned
|
Beneficial Ownership Percentage
|
Ronald
T. Nixon (1)
|
3,416,587
|
56.7%
|
James
W Stuckert (2)
|
941,584
|
15.6%
|
S.
Oden “Denny” Howell Jr. (3)
|
481,165
|
8.0%
|
J.
Michael Carmena (4)
|
5,000
|
0.1%
|
Zachery
Fleming (5)
|
2,000
|
0.0%
|
Michael
D. McNeil (6)
|
1,000
|
0.0%
|
All directors and executive officers as a group (6
persons)
|
4,847,336
|
80.5%
|
Exhibit No.
|
|
Description
|
|
|
|
|
Share
Exchange Agreement between Catalyst CellerateRX, LLC and WNDM
Medical Inc. (Incorporated by reference to Exhibit 2.1 to the
Company’s Current Report on Form 8-K dated March 21,
2019).
|
|
|
|
|
|
Articles
of Incorporation of Sanara MedTech Inc. (incorporated by reference
to Exhibit 3.1 to the Registrant’s Registration Statement on
Form S-1 filed April 11, 2008).
|
|
|
|
|
|
Amendment
to Articles of Incorporation of Sanara MedTech Inc. (incorporated
by reference to Exhibit A to the Registrant’s Information
Statement filed with the Commission on May 13, 2008).
|
|
|
|
|
|
Amendment
to Articles of Incorporation of Sanara MedTech Inc., effective
February 20, 2015 (incorporated by reference to Exhibit 4.4 to the
Registrant’s Registration Statement on Form S-8, filed with
the Commission February 21, 2020).
|
|
|
|
|
|
Amendment
to Articles of Incorporation of Sanara MedTech Inc. effective May
10, 2019 (incorporated by reference to Exhibit 4.4 to the
Registrant’s Registration Statement on Form S-8, filed with
the Commission February 21, 2020).
|
|
|
|
|
|
Bylaws
(Incorporated by reference to Exhibit 3.2 to the Company’s
Registration Statement on Form S-1 filed April 11,
2008)
|
|
|
|
|
|
Certificate
of Designations, of Series F Convertible Preferred Stock
(Incorporated by reference to Exhibit 4.1 to the Company’s
Current Report on Form 8-K filed March 21, 2019)
|
|
|
|
|
10.1 †
|
|
Wound
Management Technologies, Inc. 2010 Omnibus Long-Term Incentive Plan
dated March 12, 2010 effective subject to shareholder approval on
or before March 11, 2011 (Incorporated by reference to Exhibit 4.1
to the Company’s Quarterly Report on Form 10-Q filed August
16, 2010)
|
|
|
|
10.2 *†
|
|
Employment
Agreement dated June 1, 2019 between Sanara MedTech Inc. and Shawn
M. Bowman
|
|
|
|
10.3 *†
|
|
Employment
Agreement dated June 1, 2019 between Sanara MedTech Inc. and
Zachary B. Fleming
|
|
|
|
|
Contribution
Agreement dated August 27, 2018 between Wound Care Innovations, LLC
and Catalyst Cellerate RX, LLC (Incorporated by reference to
Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q
filed November 14, 2018)
|
|
|
|
|
|
Operating
Agreement dated August 27, 2018 between Wound Care Innovations, LLC
and Catalyst Cellerate RX, LLC (Incorporated by reference to
Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q
filed November 14, 2018)
|
|
|
|
|
|
Sublicense
Agreement dated August 27, 2018 between Catalyst Cellerate RX, LLC
and Cellerate, LLC (Incorporated by reference to Exhibit 10.3 to
the Company’s Quarterly Report on Form 10-Q filed November
14, 2018)
|
|
|
|
|
|
Professional
Services Agreement dated August 27, 2018 between Wound Management
Technologies, Inc., Catalyst Cellerate RX, LLC and Cellerate, LLC
(Incorporated by reference to Exhibit
10.4 to the Company’s Quarterly Report on Form 10-Q filed
November 14, 2018)
|
|
|
|
|
|
Convertible
Promissory Note to Catalyst Cellerate RX, LLC (Incorporated by reference to Exhibit 10.5 to the
Company’s Quarterly Report on Form 10-Q filed November 14,
2018)
|
|
|
|
|
|
Product
License Agreement dated July 8, 2019 between Sanara MedTech Inc.
and Rochal Industries, LLC (Incorporated by reference to Exhibit
10.1 to the Company’s Quarterly Report on Form 10-Q filed on
August 14, 2019)
|
|
|
|
|
|
Product
License Agreement dated October 1, 2019 between Sanara MedTech Inc.
and Rochal Industries, LLC (Incorporated by reference to Exhibit
10.1 to the Company’s Quarterly Report on Form 10-Q filed on
November 14, 2019)
|
|
|
|
|
|
List of
Subsidiaries*
|
|
|
|
|
|
Certification
of Principal Executive Officer in accordance with 18 U.S.C. Section
1350, as adopted by Section 302 of the Sarbanes-Oxley Act of
2002*
|
|
|
|
|
|
Certification
of Principal Financial Officer in accordance with 18 U.S.C. Section
1350, as adopted by Section 302 of the Sarbanes-Oxley Act of
2002*
|
|
|
|
|
|
Certification
of Principal Executive Officer in accordance with 18 U.S.C. Section
1350, as adopted by Section 906 of the Sarbanes-Oxley Act of
2002*
|
|
|
|
|
|
Certification
of Principal Financial Officer in accordance with 18 U.S.C. Section
1350, as adopted by Section 906 of the Sarbanes-Oxley Act of
2002*
|
|
|
|
|
101
|
|
Interactive Data Files pursuant to Rule 405 of Regulation
S-T
|
|
SANARA MEDTECH INC.
|
|
|
|
|
|
|
March
26, 2020
|
By:
|
/s/ Michael
McNeil
|
|
|
|
Michael
McNeil
|
|
|
|
Chief
Financial Officer
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ J.
Michael Carmena
|
|
PEO
(Principal Executive Officer)
|
|
March
26, 2020
|
J. Michael Carmena
|
|
|
|
|
|
|
|
|
|
/s/ Michael
McNeil
|
|
Chief
Financial Officer (Principal Financial and Accounting
Officer)
|
|
March
26, 2020
|
Michael
McNeil
|
|
|
|
|
|
|
|
|
|
/s/ James
W. Stuckert
|
|
Director
|
|
March
26, 2020
|
James
W. Stuckert
|
|
|
|
|
|
|
|
|
|
/s/ Ronald
T. Nixon
|
|
Chairman
|
|
March
26, 2020
|
Mr.
Ronald T. Nixon
|
|
|
|
|
|
|
|
|
|
/s/
Kenneth E. Thorpe
|
|
Director
|
|
March
26, 2020
|
Kenneth
E. Thorpe
|
|
|
|
|
|
|
|
|
|
/s/ Ann
Beal Salamone
|
|
Director
|
|
March
26, 2020
|
Ann
Beal Salamone
|
|
|
|
|
|
|
|
|
|
/s/ Oden
Howell, Jr.
|
|
Director
|
|
March
26, 2020
|
Oden
Howell, Jr.
|
|
|
|
|